Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Ac-Arg-Leu-Arg-AMC (HB3733)
Description:Fluorogenic tri-peptide substrate. Useful for measuring trypsin-like 20S proteasome peptidase activity.
Purity:>97%
Amastatin hydrochloride (HB3757)
Description:Competitive aminopeptidase (AP) inhibitor
Purity:>98%
Calyculin A (HB0161)
Description:Potent, selective protein phosphatase 1 / 2A inhibitor
Purity:>98%
Camostat mesylate (HB3595)
Description:Serine protease inhibitor. Inhibits TMPRSS2 and partially blocks SARS-Cov2 entry in vitro.
Purity:>98%
clasto-Lactacystin β-lactone (HB3842)
Description:Potent, selective and irreversible proteasome inhibitor
Purity:>95%